Psychedelic Therapeutics Clinical Trials Research Report - GlobeNewswire
The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.
Reference News
The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), Yale University as top non-industry, Johnson & Johnson as top industry, and CNS as top therapy area (92%). The US leads in trials, and Phase II trials dominate since 2013.
The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.